Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
111 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2017, provides an overview of the Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline landscape. Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to muscle cells. Without the proper input from the motor neurons, muscle cells cannot function properly. The muscle cells will, therefore, become much smaller (atrophy) and will produce symptoms of muscle weakness. This can affect walking, crawling, breathing, swallowing, and head and neck control. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 2, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively. Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Muscular Atrophy (SMA) (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Spinal Muscular Atrophy (SMA) (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Spinal Muscular Atrophy (SMA) - Overview Spinal Muscular Atrophy (SMA) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Spinal Muscular Atrophy (SMA) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Spinal Muscular Atrophy (SMA) - Companies Involved in Therapeutics Development AveXis Inc Cytokinetics Inc F. Hoffmann-La Roche Ltd Genethon SA Genzyme Corp Ionis Pharmaceuticals Inc Kowa Company Ltd Neurotune AG Novartis AG Paratek Pharmaceuticals Inc RaNA Therapeutics Inc Sarepta Therapeutics Inc Spotlight Innovation Inc WAVE Life Sciences Ltd Spinal Muscular Atrophy (SMA) - Drug Profiles AAD-2004 - Drug Profile Product Description Mechanism Of Action R&D Progress ALB-111 - Drug Profile Product Description Mechanism Of Action R&D Progress Antisense Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile Product Description Mechanism Of Action R&D Progress Antisense Oligonucleotides for Spinal Muscular Atrophy - Drug Profile Product Description Mechanism Of Action R&D Progress AVXS-101 - Drug Profile Product Description Mechanism Of Action R&D Progress CK-2127107 - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate SMN for Spinal Muscular Atrophy - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Drug Profile Product Description Mechanism Of Action R&D Progress K-828SP - Drug Profile Product Description Mechanism Of Action R&D Progress LMI-070 - Drug Profile Product Description Mechanism Of Action R&D Progress NT-1654 - Drug Profile Product Description Mechanism Of Action R&D Progress nusinersen - Drug Profile Product Description Mechanism Of Action R&D Progress olesoxime - Drug Profile Product Description Mechanism Of Action R&D Progress Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile Product Description Mechanism Of Action R&D Progress Oligonucleotides to Activate SMN2 for Spinal Muscular Atrophy Type 1 - Drug Profile Product Description Mechanism Of Action R&D Progress PMO-25 - Drug Profile Product Description Mechanism Of Action R&D Progress PTKSMA-1 - Drug Profile Product Description Mechanism Of Action R&D Progress RG-7800 - Drug Profile Product Description Mechanism Of Action R&D Progress RG-7916 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Central Nervous System Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Spinal Muscular Atrophy - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Spinal Muscular Atrophy - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit GSK-3 for Spinal Muscular Atrophy - Drug Profile Product Description Mechanism Of Action R&D Progress STL-182 - Drug Profile Product Description Mechanism Of Action R&D Progress tirasemtiv - Drug Profile Product Description Mechanism Of Action R&D Progress Spinal Muscular Atrophy (SMA) - Dormant Projects Spinal Muscular Atrophy (SMA) - Discontinued Products Spinal Muscular Atrophy (SMA) - Product Development Milestones Featured News & Press Releases Feb 08, 2017: Spotlight Innovation Engages Top-Tier Contract Research Organization to Conduct Preclinical Studies of STL-182 Jan 13, 2017: New Data Show SPINRAZA (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy Jan 06, 2017: RG7916 Granted Orphan Drug Designation in the U.S. for the Treatment of Spinal Muscular Atrophy Jan 05, 2017: PTC Therapeutics Announces Initiation of FIREFISH Study in Infant (Type I) SMA Patients Dec 28, 2016: Biogen's atrophy drug SPINRAZA to cost $750,000 per patient Dec 23, 2016: FDA approves first drug for spinal muscular atrophy Dec 06, 2016: Study Finds New Treatment For Spinal Muscular Atrophy Safe For Infants Nov 07, 2016: Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy Oct 28, 2016: Biogen's Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA Oct 20, 2016: Spinal Muscular Atrophy Program Advances into Phase 2 Clinical Studies in SMA Patients with RG7916 Oct 08, 2016: New Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spinal Muscular Atrophy Sep 26, 2016: Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy Sep 23, 2016: CHMP of the EMA has Granted Nusinersen Accelerated Assessment Aug 04, 2016: Candidate Drug for Spinal Muscular Atrophy, with Roots in CSHL Research, Passes Major Hurdle Aug 01, 2016: Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Spinal Muscular Atrophy (SMA), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Spinal Muscular Atrophy (SMA) - Pipeline by AveXis Inc, H1 2017 Spinal Muscular Atrophy (SMA) - Pipeline by Cytokinetics Inc, H1 2017 Spinal Muscular Atrophy (SMA) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Spinal Muscular Atrophy (SMA) - Pipeline by Genethon SA, H1 2017 Spinal Muscular Atrophy (SMA) - Pipeline by Genzyme Corp, H1 2017 Spinal Muscular Atrophy (SMA) - Pipeline by Ionis Pharmaceuticals Inc, H1 2017 Spinal Muscular Atrophy (SMA) - Pipeline by Kowa Company Ltd, H1 2017 Spinal Muscular Atrophy (SMA) - Pipeline by Neurotune AG, H1 2017 Spinal Muscular Atrophy (SMA) - Pipeline by Novartis AG, H1 2017 Spinal Muscular Atrophy (SMA) - Pipeline by Paratek Pharmaceuticals Inc, H1 2017 Spinal Muscular Atrophy (SMA) - Pipeline by RaNA Therapeutics Inc, H1 2017 Spinal Muscular Atrophy (SMA) - Pipeline by Sarepta Therapeutics Inc, H1 2017 Spinal Muscular Atrophy (SMA) - Pipeline by Spotlight Innovation Inc, H1 2017 Spinal Muscular Atrophy (SMA) - Pipeline by WAVE Life Sciences Ltd, H1 2017 Spinal Muscular Atrophy (SMA) - Dormant Projects, H1 2017 Spinal Muscular Atrophy (SMA) - Dormant Projects, H1 2017 (Contd..1), H1 2017 Spinal Muscular Atrophy (SMA) - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
